NCT02515955 - A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JNJ-54175446 in Healthy Male Participants | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 31, 2015

Primary Completion Date

March 31, 2016

Study Completion Date

March 31, 2016

Conditions

Healthy

Interventions

DRUG

JNJ-54175446

Participants will receive JNJ-54175446, at increasing dose levels using 2 oral formulations i.e. 0.5 mg/ml and 20 mg/ml as suspension for oral dose once daily.

DRUG

Minocycline

Participants will receive minocycline 100 mg as capsule twice daily.

DRUG

JNJ 54175446 Matching Placebo

Participants will receive placebo matching with JNJ 54175446 once daily orally.

DRUG

D Amphetamine

Participants will receive 20 mg d-amphetamine (AMPH) 2 hours after administration of study drug (JNJ-54175446/placebo or minocycline/placebo) on Day 7 and Day 10.

DRUG

D Amphetamine Matching Placebo

Participants will receive d-amphetamine (AMPH) matching placebo, 2 hours after administration of study drug (JNJ-54175446/placebo or minocycline/placebo) on Day 7 and Day 10.

Trial Locations (1)

Unknown

Leiden